This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

RON Antibody Program

ASLAN Pharmaceuticals Pte Ltd

Drug Names(s): Recepteur d’Origine Nantais Antibody Program

Description: ASLAN Pharmaceuticals is developing a novelimmuno-oncology antibody, targeting RON (Recepteur d’Origine Nantais), licensed from Singapore’s Agency for Science, Technology and Research (A*STAR).

Deal Structure: ASLAN and A*STAR
In September 2016, ASLAN Pharmaceuticals announced the licensing of a novel immuno-oncology antibody, targeting RON (Recepteur dOrigine Nantais), from Singapores Agency for Science, Technology and Research (A*STAR) which ASLAN will develop and commercialise worldwide. Under the terms of the agreement, ASLAN will gain global rights to develop the RON antibody. Commercial terms were not disclosed.


RON Antibody Program News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug